Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Homerun Slides: Clinical presentation library Previous | All Articles This Week | Next
This article originally posted 02 July, 2012 and appeared in  Medication SlidesGLP-1Diabetes Clinical Mastery Series Issue 91SGLT2

Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 1 of 2

DCMS91HS 

Part 1 of this two-part series covers some of the newest therapies for type 2 diabetes including GLP-1 agonists and DPP-4 inhibitors. We also take a look at some of the even newer therapies on the horizon such as SGLT2 inhibitors, ultra long-acting insulin (degludec) and interleukin-1 blocker, diacerein. 

Link to download (.ppt format): Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 1 of 2.

Other sets in this series:

Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 2 of 2

Check out all of Diabetes In Control's slide collections at our Clinical Presentations Library.

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 02 July, 2012 and appeared in  Medication SlidesGLP-1Diabetes Clinical Mastery Series Issue 91SGLT2

Past five issues: Diabetes Clinical Mastery Series Issue 207 | Issue 747 | Diabetes Clinical Mastery Series Issue 206 | SGLT-2 Inhibitors Special Edition September 2014 | Issue 746 |

2014 Most Popular Articles:

Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
Empagliflozin (Jardiance) SGLT-2 Inhibitor Now Available in Pharmacies
Posted August 29, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
FDA Approves Bupropion/Naltrexone (Contrave) for Obesity by Orexigen Therapeutics
Posted September 12, 2014
Pistachios Associated with an Improved Metabolic Risk Profile in Prediabetes
Posted August 29, 2014
Predicting Which Diabetics Will Develop Major Complications
Posted September 05, 2014
New Ultra-Rapid-Acting Insulin Formulation
Posted August 22, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?



Search Articles On Diabetes In Control